Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:19 AM
Ignite Modification Date:
2025-12-25 @ 1:19 AM
NCT ID:
NCT00714493
Eligibility Criteria:
Inclusion Criteria:
* Patients must have rheumatoid arthritis
* Patients must have greater than or equal to 6 tender joints and greater than or equal to 6 swollen joints
* Patients must have inadequate disease response to etanercept or adalimumab
* Patients must have received etanercept or adalimumab in combination with methotrexate for a minimum of at least 3 months prior to the screening visit. The last dose of etanercept must have been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion.
Exclusion Criteria:
* Patients who have a history of latent or active TB
* Have inflammatory disease other than rheumatoid arthritis
* Have had a chronic or recurrent infectious disease.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00714493
Study Brief:
Protocol Section:
NCT00714493